Table 2. Antipsychotic Treatment in Youths With ADHD Who Received Stimulant Treatment Before Antipsychotic Initiationa,b.
| Group | No. | Stimulant, % (95% CI)c,d | ||
|---|---|---|---|---|
| None | 1 Class | Both Classes | ||
| Total | 4869 | 47.9 (46.5-49.3) | 43.8 (42.4-45.1) | 8.4 (7.6-9.1) |
| Sex | ||||
| Male | 3032 | 47.8 (46.0-49.6) | 43.5 (41.7-45.2) | 8.7 (7.7-9.8) |
| Female | 1837 | 48.1 (45.8-50.4) | 44.2 (41.9-46.5) | 7.7 (6.5-9.0) |
| Age, y | ||||
| 3-5 | 432 | 38.4 (33.8-43.0) | 44.9 (40.2-49.6) | 16.7 (13.2-20.2) |
| 6-12 | 1459 | 46.7 (44.1-49.2) | 42.2 (39.6-44.7) | 11.2 (9.6-12.8) |
| 13-18 | 1832 | 52.7 (50.4-55.0) | 41.0 (38.7-43.3) | 6.3 (5.2-7.5) |
| 19-24 | 1146 | 45.4 (42.5-48.3) | 49.7 (46.8-52.6) | 4.9 (3.6-6.1) |
Abbreviation: ADHD, attention-deficit/hyperactivity disorder.
a
2010-2015, MarketScan Data.
b
Antipsychotic prescription during the 365 days following a new diagnosis of ADHD.
c
Presence or absence of any psychostimulant (methylphenidate or amphetamine derivate) on or before the first antipsychotic prescription.
d
Classes of the medications were methylphenidate and amphetamine derivative.